BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma (Nasdaq: BBIO) has announced new equity grants approved by its compensation committee on March 19, 2025. The grants consist of restricted stock units totaling 30,782 shares, awarded to 10 new employees.
The vesting schedule specifies that one-fourth of each employee's shares will vest on February 16, 2026, followed by quarterly vesting of one-twelfth of the remaining shares, contingent on continued employment. These inducement grants were made under BridgeBio's Amended and Restated 2019 Inducement Equity Plan, in accordance with Nasdaq Listing Rule 5635(c)(4).
BridgeBio Pharma (Nasdaq: BBIO) ha annunciato nuove concessioni di azioni approvate dal suo comitato di compensazione il 19 marzo 2025. Le concessioni consistono in unità azionarie vincolate per un totale di 30.782 azioni, assegnate a 10 nuovi dipendenti.
Il programma di maturazione specifica che un quarto delle azioni di ciascun dipendente maturerà il 16 febbraio 2026, seguito da una maturazione trimestrale di un dodicesimo delle azioni rimanenti, a condizione di continuare a essere impiegati. Queste concessioni di indennità sono state effettuate nell'ambito del Piano di Indennità Azionaria Modificato e Riformulato del 2019 di BridgeBio, in conformità con la Regola di Quotazione Nasdaq 5635(c)(4).
BridgeBio Pharma (Nasdaq: BBIO) ha anunciado nuevas concesiones de acciones aprobadas por su comité de compensación el 19 de marzo de 2025. Las concesiones consisten en unidades de acciones restringidas que totalizan 30,782 acciones, otorgadas a 10 nuevos empleados.
El cronograma de adquisición especifica que una cuarta parte de las acciones de cada empleado se adquirirán el 16 de febrero de 2026, seguido de una adquisición trimestral de un duodécimo de las acciones restantes, condicionado a la continuación del empleo. Estas concesiones de inducción se realizaron bajo el Plan de Inducción de Acciones Modificado y Reformulado de 2019 de BridgeBio, de acuerdo con la Regla de Cotización Nasdaq 5635(c)(4).
브릿지바이오 파마 (Nasdaq: BBIO)는 2025년 3월 19일 보상 위원회에서 승인한 새로운 주식 보상을 발표했습니다. 이 보상은 10명의 신규 직원에게 수여된 총 30,782주의 제한 주식 단위로 구성되어 있습니다.
주식의 취득 일정은 각 직원의 주식 4분의 1이 2026년 2월 16일에 취득되며, 이후 남은 주식의 12분의 1이 분기별로 취득되는 것으로, 지속적인 고용을 조건으로 합니다. 이러한 유인 보상은 브릿지바이오의 수정 및 재작성된 2019년 유인 주식 계획에 따라 이루어졌으며, Nasdaq 상장 규칙 5635(c)(4)에 따라 시행되었습니다.
BridgeBio Pharma (Nasdaq: BBIO) a annoncé de nouvelles attributions d'actions approuvées par son comité de rémunération le 19 mars 2025. Les attributions se composent d'unités d'actions restreintes totalisant 30 782 actions, accordées à 10 nouveaux employés.
Le calendrier d'acquisition précise qu'un quart des actions de chaque employé sera acquis le 16 février 2026, suivi d'une acquisition trimestrielle d'un douzième des actions restantes, sous réserve d'un emploi continu. Ces attributions incitatives ont été effectuées dans le cadre du Plan d'Actions Incitatives Modifié et Révisé de 2019 de BridgeBio, conformément à la Règle de Cotation Nasdaq 5635(c)(4).
BridgeBio Pharma (Nasdaq: BBIO) hat am 19. März 2025 neue Aktienvergaben angekündigt, die von seinem Vergütungsausschuss genehmigt wurden. Die Vergaben bestehen aus beschränkten Aktieneinheiten mit insgesamt 30.782 Aktien, die an 10 neue Mitarbeiter vergeben wurden.
Der Vesting-Zeitplan legt fest, dass ein Viertel der Aktien jedes Mitarbeiters am 16. Februar 2026 fällig wird, gefolgt von einer vierteljährlichen Vesting von einem Zwölftel der verbleibenden Aktien, abhängig von einer fortgesetzten Beschäftigung. Diese Anreizvergaben wurden im Rahmen des geänderten und neu gefassten Aktienplans von BridgeBio aus dem Jahr 2019 gemäß der Nasdaq-Listing-Regel 5635(c)(4) vorgenommen.
- Successful attraction of new talent with 10 new hires
- Structured equity compensation plan to retain employees
- Potential dilution from 30,782 new shares
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation committee of BridgeBio’s board of directors approved equity grants to 10 new employees in restricted stock units for an aggregate of 30,782 shares of the Company’s common stock. One-fourth of the shares underlying each employee’s restricted stock units will vest on February 16, 2026, with one-twelfth of the remaining shares underlying each such employee’s restricted stock units vesting on a quarterly basis thereafter, in each case, subject to each such employee’s continued employment with the Company or one of its subsidiaries on such vesting dates. All of the above-described awards were made under BridgeBio’s Amended and Restated 2019 Inducement Equity Plan (the “Plan”).
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by BridgeBio’s board of directors in November 2019 and amended and restated on February 10, 2023, and on December 13, 2023.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Contact:
Bubba Murarka, EVP Communications
contact@bridgebio.com
(650)-789-8220
FAQ
How many shares were granted in BridgeBio's (BBIO) March 2025 inducement grants?
What is the vesting schedule for BBIO's March 2025 restricted stock units?
When did BridgeBio (BBIO) last update its Inducement Equity Plan?
How many new employees received BBIO stock grants in March 2025?
